Drug Price Trends for NDC 00074-3346

Average Pharmacy Cost for 00074-3346

Drug Name	NDC	Price/Unit ($)	Unit	Date
LUPRON DEPOT 22.5 MG 3MO KIT	00074-3346-03	6516.29819	EACH	2026-01-02

Best Wholesale Price for NDC 00074-3346

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00074-3346

Last updated: February 15, 2026

Overview NDC 00074-3346 is the drug Liraglutide (brand name Victoza), indicated for type 2 diabetes and obesity management. Market dynamics are driven by competition, patent status, regulatory environment, and market penetration.

Market Size and Growth Global Type 2 diabetes therapeutics market was valued at approximately USD 50 billion in 2022, with a CAGR of 7% predicted through 2030. Obesity treatment markets are expanding similarly, driven by rising prevalence rates worldwide.

Key Competitors and Market Share

• Novo Nordisk’s Victoza (Liraglutide): Holds roughly 60-70% of the GLP-1 receptor agonist segment.
• Eli Lilly’s Trulicity (Dulaglutide) and other competitors like Semaglutide (Ozempic, Wegovy) claim remaining market share.
• Patent status of Victoza expired in some regions, encouraging generic entry but maintaining brand loyalty through efficacy and safety profile.

Pricing Dynamics Average wholesale price (AWP):

• Victoza (per 3 mL pen, 18 mg): USD 700– USD 750.
• Monthly treatment: Approximate USD 750– USD 800, depending on dosing and insurance coverage.

Pricing trends:

• Generic entry: Expected to reduce prices by 20–40% over next two years if approved.
• Market competition: Newer drugs (e.g., Semaglutide) are priced higher initially (USD 850– USD 1,000 per month), pressuring Victoza’s price.

Regulatory and Patent Considerations

• Patent expiration in Europe occurred in 2017 and in the U.S. in 2023 for certain formulations.
• Biosimilar market entry is anticipated within the next 1–2 years, likely impacting pricing and market share.

Market Penetration

• Established presence in both type 2 diabetes and obesity segments.
• Growing adoption driven by favorable efficacy profiles and cardiovascular benefits.
• Market expansion via increased use in obesity, driven by approval of higher doses and new indications.

Price Projections (Next 3 Years)	Year	Price Range (USD per 3 mL pen)	Market Share %	Notes
2023	700–750	70	Price stabilized post patent expiry; competition from biosimilars emerging.
2024	600–700	65	Entry of biosimilars likely; price reductions ensue.
2025	550–650	60	Increased biosimilar market penetration; pricing pressure intensifies.

Key Factors Affecting Price

• Biosimilar approval and acceptance.
• Physician preference and patient loyalty.
• Insurance reimbursement policies.
• Severity of market competition from newer agents.

Strategic Outlook Brands that adapt to biosimilar market entries and leverage ongoing clinical benefits will sustain market share. Price discounts will remain a critical component for competitiveness, especially in payor-driven markets.

Key Takeaways

• Victoza maintains leadership but faces pressures from biosimilars and newer GLP-1 drugs.
• Prices are expected to decline gradually over the next three years, with discounts up to 40% possible.
• Patent expiry and biosimilar approval in key markets will reshape the competitive landscape.
• Market expansion into obesity management increases revenue potential.
• Payer strategies heavily influence actual patient access and net prices.

FAQs

1. When will biosimilars for Victoza become available?

   • Biosimilar development is progressing; approval could occur within 1–2 years, pending regulatory review.

2. How has the patent expiry affected Victoza's market share?

   • Patent expiry typically reduces exclusivity, resulting in increased competition and downward pricing pressure.

3. Are future price reductions likely to impact treatment adherence?

   • Reduced prices can improve access, potentially increasing adherence and overall market size.

4. What are the key drivers for Victoza's market retention?

   • Proven efficacy, cardiovascular benefits, and physician familiarity.

5. How does the obesity market influence Victoza pricing and sales?

   • Expansion into obesity management elevates revenue opportunities but may introduce new competitors and pricing strategies.

References

1. MarketWatch, "Global Diabetes Drugs Market Size," 2022.
2. IQVIA, "Pharmaceutical Market Data," 2023.
3. FDA Briefing, "Biosimilar Guidance," 2023.
4. Novo Nordisk Annual Report, 2022.
5. EvaluatePharma, "GLP-1 Receptor Agonist Market Review," 2023.